SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ADVENTRX Pharmaceuticals Inc (Anx)
An SI Board Since March 2006
Posts SubjectMarks Bans Symbol
418 6 0 ANX
Emcee:  Ruffian Type:  Moderated
Introduction Market Data Compact
ADVENTRX Pharmaceuticals, Inc. operates as a biopharmaceutical research and development company. The company focuses on new technologies for anticancer and antiviral treatments, which address drug metabolism, toxicity, bioavailability, or resistance problems. Its lead product includes CoFactor, a folate-based biomodulator drug, which is used for the treatment of metastatic GI and breast cancers, metastatic colorectal cancer, and metastatic pancreatic cancer. CoFactor is tested with 5-FU in a U.S. based Phase II and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor received clearance under a special protocol assessment from the U.S. FDA for a Phase III pivotal clinical trial for metastatic colorectal cancer. ADVENTRX Pharmaceuticals also has an exclusive license from the University of Southern California to develop and commercialize CoFactor. The company, formerly known as Biokeys Pharmaceuticals, Inc., was organized in 1995 and changed its name to ADVENTRX Pharmaceuticals, Inc. in 2003. ADVENTRX Pharmaceuticals is based in San Diego, California.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
418ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Applicationmlkr3/2/2010
417Pulled back to 020 after FDA's rejection of application> But has second mlkr3/2/2010
416Another "pumpa" site recs it besides beacon equity! Adventrx Pharmaceumlkr1/11/2010
415Reversal to upward trend again! over 60 m shares ,, 040s.. againmlkr1/11/2010
414Raising new capital... Almost 20 m..Now NDA news yet!mlkr1/4/2010
413Today is the last day of the year -- deadline for submission of NDA if they can mlkr12/31/2009
412It is nice to see new postings on this board. It has been a long time since a pbuffalodon200312/31/2009
411News any hour for NDA ? crucial! 040 !mlkr12/30/2009
410me angry? no mas................Ruffian3/27/2009
409Hey Ruffian What do you think about OUR stock now? When do you think we will hepowersurgeongeneral3/27/2009
408agree 100%................Ruffian3/20/2009
407Down to 5 people, looks like they are lining up for a sale as opposed to any kinKeith Feral3/20/2009
406"Along with the reductions we implemented in October 2008 and January 2009,Ruffian3/20/2009
405By the way Ruffian i have no knowledge to counter your statement about thornleypowersurgeongeneral3/18/2009
404Ruffian, i just saw your pm (been hunkered down) and cannot respond privately Topowersurgeongeneral3/18/2009
403hey Ruffian, any news on anx?powersurgeongeneral3/18/2009
402Brian M. Culley Other Executive Officer/Senior VP/CEO ADVENTRX Pharmaceuticals, Ruffian2/15/2009
401And it keeps moving today!Keith Feral2/11/2009
400ADVENTRX Provides Update on Strategic Transaction Process Tuesday February 10, 9Ruffian2/10/2009
399Thanks for the heads up!Keith Feral2/10/2009
398On February 10, 2009, ADVENTRX Pharmaceuticals, Inc. (the "Company") iRuffian2/10/2009
397ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study Thursday FRuffian2/5/2009
396Thornley is a Piker..........Ruffian2/5/2009
395ruffian, have you checked of airv? fem to cell i believe thornley from q is a dipowersurgeongeneral10/31/2008
394NKERuffian10/20/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News